These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 31222924)

  • 1. A CACE for assessing non-compliance: Addressing non-compliance in randomised controlled trials.
    Simmons RA; Egger JR
    BJOG; 2019 Dec; 126(13):1558-1559. PubMed ID: 31222924
    [No Abstract]   [Full Text] [Related]  

  • 2. A causal model for longitudinal randomised trials with time-dependent non-compliance.
    Becque T; White IR; Haggard M
    Stat Med; 2015 May; 34(12):2019-34. PubMed ID: 25778798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discussions.
    Vansteelandt S
    Biometrics; 2009 Sep; 65(3):686-9; discussion 689-91. PubMed ID: 18759845
    [No Abstract]   [Full Text] [Related]  

  • 4. Discussion of "Identifiability and estimation of causal effects in randomized trials with noncompliance and completely nonignorable missing data".
    Small DS; Cheng J
    Biometrics; 2009 Sep; 65(3):682-6; discussion 689-91. PubMed ID: 18759846
    [No Abstract]   [Full Text] [Related]  

  • 5. Identifiability and estimation of causal effects in randomized trials with noncompliance and completely nonignorable missing data.
    Chen H; Geng Z; Zhou XH
    Biometrics; 2009 Sep; 65(3):675-82. PubMed ID: 18759847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Bayesian hierarchical model estimating CACE in meta-analysis of randomized clinical trials with noncompliance.
    Zhou J; Hodges JS; Suri MFK; Chu H
    Biometrics; 2019 Sep; 75(3):978-987. PubMed ID: 30690716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating treatment effects in randomised controlled trials with non-compliance: a simulation study.
    Ye C; Beyene J; Browne G; Thabane L
    BMJ Open; 2014 Jun; 4(6):e005362. PubMed ID: 24939814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of non-compliance on intent-to-treat analysis of equivalence trials.
    Sheng D; Kim MY
    Stat Med; 2006 Apr; 25(7):1183-99. PubMed ID: 16220491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model misspecification sensitivity analysis in estimating causal effects of interventions with non-compliance.
    Jo B
    Stat Med; 2002 Nov; 21(21):3161-81. PubMed ID: 12375297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of methods for estimating the causal effect of a treatment in randomized clinical trials subject to noncompliance.
    Little RJ; Long Q; Lin X
    Biometrics; 2009 Jun; 65(2):640-9. PubMed ID: 18510650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regaining power lost by non-compliance via full probability modelling.
    Becque T; White IR
    Stat Med; 2008 Nov; 27(27):5640-63. PubMed ID: 18712776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A note on 'The method of handling non-compliance in clinical trials suggested by Sato/Matsuyama'.
    Sjölander A
    Stat Med; 2008 Aug; 27(19):3920-4. PubMed ID: 18407577
    [No Abstract]   [Full Text] [Related]  

  • 13. Weighting in instrumental variables and G-estimation.
    Joffe MM; Brensinger C
    Stat Med; 2003 Apr; 22(8):1285-303. PubMed ID: 12687655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond intent to treat (ITT): A complier average causal effect (CACE) estimation primer.
    Peugh JL; Strotman D; McGrady M; Rausch J; Kashikar-Zuck S
    J Sch Psychol; 2017 Feb; 60():7-24. PubMed ID: 28164801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correcting for non-compliance in randomized non-inferiority trials with active and placebo control using structural models.
    Wu Y; Zhao L; Hou Y; Li K; Zhou X
    Stat Med; 2015 Mar; 34(6):950-65. PubMed ID: 25534903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ITT analysis of randomized encouragement design studies with missing data.
    Zhou XH; Li SM
    Stat Med; 2006 Aug; 25(16):2737-61. PubMed ID: 16287216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Causal inference methods to assess safety upper bounds in randomized trials with noncompliance.
    Wang Y; Berlin JA; Pinheiro J; Wilcox MA
    Clin Trials; 2015 Jun; 12(3):265-75. PubMed ID: 25733675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity analysis of intention-to-treat estimates when withdrawals are related to unobserved compliance status.
    Salim A; Mackinnon A; Griffiths K
    Stat Med; 2008 Apr; 27(8):1164-79. PubMed ID: 17724782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dichotomizing partial compliance and increased participant burden in factorial designs: the performance of four noncompliance methods.
    Merrill PD; McClure LA
    Trials; 2015 Nov; 16():523. PubMed ID: 26573840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimation of treatment efficacy with complier average causal effects (CACE) in a randomized stepped wedge trial.
    Gruber JS; Arnold BF; Reygadas F; Hubbard AE; Colford JM
    Am J Epidemiol; 2014 May; 179(9):1134-42. PubMed ID: 24705812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.